Ticker: LIXT

Lixte Biotechnology Holdings, Inc. (OTCBB: LIXT) focuses on developing cancer therapies, particularly through its lead compound, LB-100, which inhibits Protein Phosphatase 2A to enhance the efficacy of existing treatments. Recent Financial Highlights (Q1 2025): Revenues: $0 - No revenue generate...